Literature DB >> 23058914

Identification of CK2 as the kinase that phosphorylates Pax3 at Ser209 in early myogenic differentiation.

Aditi S Iyengar1, Jacob M Loupe, Patrick J Miller, Andrew D Hollenbach.   

Abstract

The myogenic transcription factor Pax3, a member of the paired class homeodomain family of transcription factors, plays an essential role in early skeletal muscle development. We previously demonstrated that Pax3 is phosphorylated at three specific residues (Ser201, Ser205, and Ser209) and that the pattern of phosphorylation at these sites changes throughout early myogenesis. Further, we demonstrated that the protein kinase CK2 phosphorylates Pax3 at Ser205 and that this phosphorylation event is required for the subsequent phosphorylation of Ser201 by GSK3β. However, the kinase that phosphorylates Pax3 at Ser209 has yet to be identified. In the present work we use standard purification methods and in vitro biochemical analyses to provide solid evidence identifying the protein kinase CK2 as phosphorylating Pax3 at Ser209. Further, we qualitatively demonstrate that the phosphorylation of Pax3 at Ser209 by CK2 is enhanced when Ser205 is previously phosphorylated. Taken together, our results allow us to propose a mechanism to describe the ordered phosphorylation of Pax3 throughout early myogenesis.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23058914      PMCID: PMC3500634          DOI: 10.1016/j.bbrc.2012.09.141

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  17 in total

Review 1.  Cyclin-dependent kinases as cellular targets for antiviral drugs.

Authors:  Luis M Schang
Journal:  J Antimicrob Chemother       Date:  2002-12       Impact factor: 5.790

Review 2.  One-thousand-and-one substrates of protein kinase CK2?

Authors:  Flavio Meggio; Lorenzo A Pinna
Journal:  FASEB J       Date:  2003-03       Impact factor: 5.191

3.  Ribofuranosyl-benzimidazole derivatives as inhibitors of casein kinase-2 and casein kinase-1.

Authors:  F Meggio; D Shugar; L A Pinna
Journal:  Eur J Biochem       Date:  1990-01-12

4.  Development of a lethal congenital heart defect in the splotch (Pax3) mutant mouse.

Authors:  S J Conway; D J Henderson; M L Kirby; R H Anderson; A J Copp
Journal:  Cardiovasc Res       Date:  1997-11       Impact factor: 10.787

Review 5.  Protein kinases. 4. Protein kinase CK2: an enzyme with multiple substrates and a puzzling regulation.

Authors:  J E Allende; C C Allende
Journal:  FASEB J       Date:  1995-03       Impact factor: 5.191

6.  Cyclin C/CDK8 and cyclin H/CDK7/p36 are biochemically distinct CTD kinases.

Authors:  P Rickert; J L Corden; E Lees
Journal:  Oncogene       Date:  1999-01-28       Impact factor: 9.867

7.  Phosphorylation of serine 205 by the protein kinase CK2 persists on Pax3-FOXO1, but not Pax3, throughout early myogenic differentiation.

Authors:  Kevin N Dietz; Patrick J Miller; Andrew D Hollenbach
Journal:  Biochemistry       Date:  2009-12-15       Impact factor: 3.162

8.  Characterization of the Schizosaccharomyces pombe Cdk9/Pch1 protein kinase: Spt5 phosphorylation, autophosphorylation, and mutational analysis.

Authors:  Yi Pei; Stewart Shuman
Journal:  J Biol Chem       Date:  2003-08-05       Impact factor: 5.157

9.  Pax-3 is required for the development of limb muscles: a possible role for the migration of dermomyotomal muscle progenitor cells.

Authors:  E Bober; T Franz; H H Arnold; P Gruss; P Tremblay
Journal:  Development       Date:  1994-03       Impact factor: 6.868

10.  Role of Pax3 acetylation in the regulation of Hes1 and Neurog2.

Authors:  Shunsuke Ichi; Vanda Boshnjaku; Yueh-Wei Shen; Barbara Mania-Farnell; Sara Ahlgren; Sidanth Sapru; Nikhita Mansukhani; David G McLone; Tadanori Tomita; C S K Mayanil
Journal:  Mol Biol Cell       Date:  2010-12-17       Impact factor: 4.138

View more
  8 in total

1.  Protein kinase CK2 in development and differentiation.

Authors:  Claudia Götz; Mathias Montenarh
Journal:  Biomed Rep       Date:  2016-12-19

2.  Protein kinase CK2 subunits exert specific and coordinated functions in skeletal muscle differentiation and fusogenic activity.

Authors:  Valentina Salizzato; Sofia Zanin; Christian Borgo; Elisa Lidron; Mauro Salvi; Rosario Rizzuto; Giorgia Pallafacchina; Arianna Donella-Deana
Journal:  FASEB J       Date:  2019-07-03       Impact factor: 5.834

3.  Inhibiting phosphorylation of the oncogenic PAX3-FOXO1 reduces alveolar rhabdomyosarcoma phenotypes identifying novel therapy options.

Authors:  J M Loupe; P J Miller; D R Ruffin; M W Stark; A D Hollenbach
Journal:  Oncogenesis       Date:  2015-03-30       Impact factor: 7.485

4.  BRAF activates PAX3 to control muscle precursor cell migration during forelimb muscle development.

Authors:  Jaeyoung Shin; Shuichi Watanabe; Soraya Hoelper; Marcus Krüger; Sawa Kostin; Jochen Pöling; Thomas Kubin; Thomas Braun
Journal:  Elife       Date:  2016-12-01       Impact factor: 8.140

Review 5.  Regulation of the Mammalian SWI/SNF Family of Chromatin Remodeling Enzymes by Phosphorylation during Myogenesis.

Authors:  Teresita Padilla-Benavides; Pablo Reyes-Gutierrez; Anthony N Imbalzano
Journal:  Biology (Basel)       Date:  2020-07-03

6.  CK2-Dependent Phosphorylation of the Brg1 Chromatin Remodeling Enzyme Occurs during Mitosis.

Authors:  Teresita Padilla-Benavides; Dominic T Haokip; Yeonsoo Yoon; Pablo Reyes-Gutierrez; Jaime A Rivera-Pérez; Anthony N Imbalzano
Journal:  Int J Mol Sci       Date:  2020-01-30       Impact factor: 5.923

7.  Ck2-Dependent Phosphorylation Is Required to Maintain Pax7 Protein Levels in Proliferating Muscle Progenitors.

Authors:  Natalia González; James J Moresco; Felipe Cabezas; Eduardo de la Vega; Francisco Bustos; John R Yates; Hugo C Olguín
Journal:  PLoS One       Date:  2016-05-04       Impact factor: 3.240

Review 8.  Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma.

Authors:  Thanh Hung Nguyen; Frederic G Barr
Journal:  Molecules       Date:  2018-10-28       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.